In MONALEESA-2, 393 patients (59%) had visceral metastases (including liver, lung, and/or other metastatic sites) (Burris HA et al. First-line ribociclib + letrozole in patients with HR+/HER2– advanced breast cancer presenting with visceral metastases or bone-only disease: a subgroup analysis of the MONALEESA-2 trial. The gene discussed is HR; the disease is breast carcinoma.